ADVTX Presents New Treatment For Bleeding After Nuclear Exposure

Advanced Therapeutics (ADVTX) has announced that Fibrinoplate-S has shown efficacy in reducing the bleeding in animals exposed to extreme doses of radiation.

Reportedly in preclinical trials, Fibrinoplate-S reduced bleeding within 2 hours after a bolus intravenous administration in test subjects, with less than 1% of the normal platelet count. The beneficial effects last at least 24 hours.

Fibrinoplate-S can be given to a large number of patients quickly, said the company.

Richard Yen, CEO of ADVTX, said: “Acute radiation can severely damage the bone marrow. While existing medications can boost the production of red cells and white cells from the recovering bone marrow, there is no effective treatment for low concentrations of platelets except through platelet transfusion. Donor platelets, however, may not be available or adequately screened for pathogens during times of distress.”